Weikang Pharmaceutical (300878.SZ): Huangjia Ruangan Granules approved to conduct Phase III clinical trials for chronic hepatitis B liver fibrosis

Zhitong Finance APP News, Weikang Pharmaceutical (300878.SZ) announced that the company recently received the "Drug Clinical Trial Supplementary Application Approval Notice" for Huangjia Ruangan Granules approved and issued by the National Medical Products Administration. After review, the clinical trial application for Huangjia Ruangan Granules complies with the relevant requirements for drug registration. On the basis of further improving the clinical trial protocol, it is agreed to conduct a Phase III clinical trial for chronic hepatitis B liver fibrosis.